


Introduction to
Neurophysiology
(lecture 3)
Neurotransmitters


- **Fatima Ryalat, MD, PhD**

- **Assistant Professor, Physiology and Biochemistry
Department, School of Medicine, The University of Jordan**

By Abdallah Al-Saraireh



Neurotransmitter are unique to **chemical synapses**; electrical synapses rely on direct ion flow through gap junctions instead



Small-Molecule, Rapidly Acting Transmitters

Class I

Acetylcholine

Class II: The Amines

Norepinephrine

Epinephrine

Dopamine

Serotonin

Melatonin

Histamine

Class III: Amino Acids

Gamma-aminobutyric acid

Glycine

Glutamate

Aspartate

Class IV

ATP

Arachidonic acid

Nitric oxide

Carbon monoxide

"The table classifies **'Small-Molecule, Rapidly Acting Transmitters'** into four main classes based on their chemical structure. These neurotransmitters are responsible for most acute responses in the nervous system, such as sensory transmission to the brain and motor signals to the muscles."

Small-molecule

(rapid release)

Can bind to either
Ionotropic (fast) or
Metabotropic (prolonged)
receptors.

Synthesis in presynaptic
terminal (at the axon
terminal)

1 Acetylcholine (ACh) is made
from choline and acetyl CoA

2 In the synapse, ACh is rapidly
broken down by the enzyme
acetylcholinesterase (AChE)

3 Choline is transported back
into the axon terminal and
used to make more ACh


Neurotransmitters are stored in vesicles to
allow for quantal release (fixed amount)

Binding causes a
conformational change
in the receptor

Choline is the
component that
undergoes
recycling.

It is transported
back into the
axon terminal to
be reused for
synthesizing new
ACh.

While choline is actively
recycled back into the
terminal, Acetate simply
diffuses away into the
surrounding environment.



Neuropeptides

→ The second type

Hypothalamic-Releasing Hormones

Thyrotropin-releasing hormone

Luteinizing hormone-releasing hormone

Somatostatin (growth hormone inhibitory factor)

Pituitary Peptides

Adrenocorticotrophic hormone

β-Endorphin

α-Melanocyte-stimulating hormone

Prolactin

Luteinizing hormone

Thyrotropin

Growth hormone

Vasopressin

Oxytocin

From Other Tissues

Angiotensin II

Bradykinin

Carnosine

Sleep peptides

Calcitonin

Peptides that Act on Gut and Brain

Leucine enkephalin

Methionine enkephalin

Substance P

Gastrin

Cholecystokinin

Vasoactive intestinal polypeptide

Nerve growth factor

Brain-derived neurotropic factor

Neurotensin

Insulin

Glucagon

Produced at the **Soma** (Cell Body).

- **Packaging:** Enclosed within **vesicles** inside the soma (specifically in the Golgi apparatus).
- **Transport:** Moved to the terminal via **Axonal transport** (which is slower than local synthesis).
- **Receptors:** Primarily act through **GPCRs** (Metabotropic receptors).
- **Potency:** Much more potent than small molecules; you need a smaller quantity to achieve the same effect.
- **Mechanism:** Cause **Amplification** of signals within the cell, leading to prolonged effects.
- **Fate:** Vesicles are **not recycled**; they undergo *autolysis* (digestion) after release.




Neuropeptides


- synthesized in the **neuronal cell body**.
- packages into **vesicles**.
- transported along the axon to the axon terminals.
- traveling at the **slow rate**.
- vesicles release their transmitter at the neuronal terminals in response to action potential.
- Usually, the vesicle is autolyzed not reused.

Neuropeptides

- smaller quantities of neuropeptides are usually released.
- neuropeptides are generally **more potent** than the small-molecule transmitters.
- They often cause more prolonged actions.
- **Metabotropic receptors**



Nitric oxide (NO)



- **Not** presynthesized (they are not made in advance)
- **Not** pre-vesicled (they are not stored in synaptic vesicles in the presynaptic terminal)
- Formed in the presynaptic neuron when **needed** (on demand)
- Synthesized by nitric oxide synthase (NOS) enzymes

Types of NOS include:

- nNOS (**neuronal** nitric oxide synthase)
- iNOS (**includible** nitric oxide synthase)

The doctor said they are not included in the exam, but we will learn them in the next years, so why not memorize them now!

GABA

1. GABA is the main "brake" that prevents Epilepsy, which occurs when low GABA levels cause uncontrolled electrical firing.
2. It functions via two receptors: GABA-A (fast Ionic channel) and GABA-B (slow Metabo-GPCR).

- **Gamma-aminobutyric acid** (GABA).
- it is the main **inhibitory** neurotransmitter.

Very important

- Receptors: GABA-A (Cl- channel), GABA-B (GPCR)

Ionic, fast, opens the Cl- channels

G-protein Coupled Receptor

Metabo, slow, uses GPCR

- **Epilepsy** (uncontrolled electrical activity)

A chronic brain disorder

The doctor said that we don't have to memorize the receptors, but we will learn them in the next years!

Glycine

- Glycine is secreted mainly at synapses in the **spinal cord > brain**.
- It is almost always an **inhibitory** transmitter.

Quick question:

Which of the following is the primary inhibitory neurotransmitter in the spinal cord?

- A) Glutamate
- B) GABA
- C) Glycine
- D) Dopamine
- E) Acetylcholine

The answer is (C)

Very important

1. Glycine inhibits motor neurons to prevent over-contraction of muscles, ensuring smooth movement and relaxation.
2. It blocks the transmission of pain signals in the spinal cord before they reach the brain.

Glutamate

Very important



- Glutamate is the main **excitatory** neurotransmitter.

- Receptors:

(ionotropic: **AMPA**, **NMDA**), metabotropic (**mGluR**)

α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid

مو مطلوب حفظ أسماء المستقبلات ولا
الاختصارات ، لكن حطيتهم عشان نمّر
على الاسم قبل ما نشوفه بالسنوات الجاي

N-methyl-D-aspartate

Metabotropic Glutamate Receptor

The doctor said that we don't have to memorize the receptors, but we will learn them in the next years!


Acetylcholine (ACh)

- Acetylcholine is secreted by neurons in many areas of the nervous system such as:
- **motor neurons** that innervate the skeletal muscles (**NMJ: neuromuscular junction**).
- **neurons of the autonomic nervous system.**

↓
Very important

- **Basal forebrain**

↓
Very important



Receptors are:

- nicotinic (ionotropic)
- muscarinic (metabotropic: GPCR).

- In most cases, acetylcholine has an **excitatory effect.**

→ Very important


Myasthenia gravis (loss of ACh receptors at the NMJ (Muscle weakness))

Alzheimer's disease (loss of ACh-producing neurons in the brain (memory loss))

→ Very important

Norepinephrine

- Norepinephrine is secreted by the terminals of many neurons whose cell bodies are in:
- the brain stem, specifically, **locus ceruleus** that plays a role in **wakefulness** and **arousal**.
Very important
- also secreted by most postganglionic neurons of the sympathetic nervous system.

- **Depression** (low levels of it)
- **ADHD** (low levels of it)  *Very important*

Dopamine

Dopamine starts from the Brainstem (Nigra) and goes to the Striatum for movement, or to the Cortex for thinking and psychiatric control

Controls movement; its destruction leads to Parkinson's disease

- Dopamine is secreted by neurons in **nigrostriatal**, **mesolimbic**, **mesocortical**, and **tuberoinfundibular** pathways.

Regulate reward and emotion; overactivity is linked to psychiatric disorders (psychosis)

Inhibits prolactin secretion; blocking it causes high prolactin levels

- Receptors: D1-D5

D1-D5: Five types of receptors divided into Excitatory (D1, D5) and Inhibitory (D2, D3, D4) families.

- **Parkinson's disease**
- **Psychiatric disorders (motivation and emotions)**
- **Control prolactin secretion**

Dopamine from **Hypothalamus** acts on **Anterior Pituitary** to Reduce Milk (Inhibit Prolactin)

Serotonin

Serotonin, also known as 5-Hydroxytryptamine (5-HT), is secreted from the Raphe nucleus to regulate mood via 5-HT 1-7 receptors

Very important



- Secreted by **raphe nucleus** of the brainstem
- Control **mood, sleep, appetite, pain.**
- **Depression** (low levels of serotonin)
- **Receptors: 5-HT 1-7 (ionotropic and metabotropic)**

Substance P

- **Neuropeptide**
- Sensory neurons, **spinal cord**, hypothalamus
Pain transmission (**chronic pain**), inflammation and stress.

Hypothalamus: Releases Substance P during stress and emotional pain responses

Sensory Neurons: Use Substance P to transmit pain signals from the body to the Spinal Cord

Oxytocin

- **Neuropeptide**
- Produced in **hypothalamus** and Released from **posterior pituitary**.
- Control **contractions** of **uterus** during labor
- **Ejection of milk** during lactation
- **Social bonding** and **emotional behavior**

Co-transmission


Co-release

- **Slowly** acting neuropeptide transmitters and **rapidly** acting, small-molecule transmitters are often stored and released from **the same neurons**.
- In some cases, two or more of these transmitters are co-localized in the same synaptic vesicles and are co-released when an action potential reaches the presynaptic terminal.

Quick question:

In the context of neuronal communication, which of the following best describes the physiological phenomenon of "Co-release"?

- A) The activation of multiple postsynaptic neurons by a single neurotransmitter type.
- B) The simultaneous discharge of different neurotransmitters stored within the same synaptic vesicle.
- C) The release of neuropeptides from one neuron and small-molecule transmitters from a neighboring neuron.
- D) The enzymatic breakdown of neuropeptides in the synaptic cleft to produce small-molecule transmitters.
- E) The inhibition of (Ca^{++}) channels to prevent the release of multiple neurotransmitter types.



The answer is (B)

Co-transmission


Differential regulation

- In other cases, these transmitters may be localized in **different synaptic vesicles** of the **same neuron** and contribute to co-transmission of signals to a postsynaptic neuron.
- Moreover, their release may be **differentially regulated** because of different calcium ion sensitivities

Quick question:

In neurons utilizing co-transmission from distinct vesicle populations, how does the firing frequency of action potentials achieve differential regulation of neurotransmitter release?

- A) By altering the chemical structure of neuropeptides to fit into small-molecule vesicles.
- B) By increasing the size of the synaptic cleft to accommodate multiple transmitter types.
- C) By reversing the direction of (Ca^{++}) efflux during high-frequency stimulation.
- D) By modulating the concentration of intracellular (Ca^{++}) to meet different vesicular sensitivities.
- E) By activating postsynaptic receptors only when a single action potential occurs.




The answer is (D)

Co-transmission

Spatial segregation

- Or spatial segregation of the vesicles on different boutons



Quick question:

Which of the following best characterizes "Spatial Segregation" as a mechanism of neuronal co-transmission?

- A) The release of different neurotransmitters from the same synaptic vesicle into the cleft.
- B) The distribution of distinct neurotransmitter types into separate axonal terminals (boutons) of a single neuron.
- C) The requirement of high-frequency action potentials to release all transmitter types from a single bouton.
- D) The conversion of neurotransmitters from inhibitory to excitatory depending on the target site.
- E) The storage of all neurotransmitter types in a single, large dense-core vesicle at the main axon hillock.

The answer is (B)

Summary

Feature	Co-release	Differential regulation	Spatial segregation
Storage strategy	Same synaptic vesicles	Different vesicles in the same terminal	Different vesicles in different terminals (boutons)
Release mechanism	Simultaneous (Always together)	Frequency-dependent (low vs. high)	Branch-specific release
Ca ⁺⁺ sensitivity	Uniform for all transmitters	Different sensitivities between vesicles	Location-specific sensitivity
Action potential (AP)	Single AP triggers both	Low frequency = one type of neurotransmitters High frequency = both types	AP reaches different branches to release specific types
Main advantage	Guaranteed dual signal (وصول إشارة مزدوجة للخلية المستهدفة في وقت واحد)	Temporal control (Time-based)	Target-specific control (spatial – based)

1. Which of the following neurotransmitters is unique because it is synthesized on demand (not pre-stored in vesicles) and acts by modifying intracellular metabolic functions rather than membrane potential?

- A) Acetylcholine
- B) Gamma-aminobutyric acid (GABA)
- C) Nitric oxide (NO)
- D) Substance P
- E) Serotonin

The answer is (C)

2. A patient presents with progressive memory loss. Clinical investigation suggests a loss of neurons in the basal forebrain. Which neurotransmitter system is most likely affected?

- A) Dopaminergic system in the substantia nigra
- B) Cholinergic system (Acetylcholine)
- C) Noradrenergic system in the locus ceruleus
- D) Serotonergic system in the raphe nucleus
- E) GABAergic system in the spinal cord

The answer is (B)

3. In the clinical context of "Epilepsy", which neurotransmitter is often referred to as the main "brake" of the brain, where its deficiency leads to uncontrolled electrical firing?

- A) Glutamate
- B) Dopamine
- C) Glycine
- D) GABA
- E) Norepinephrine

The answer is (D)

4. Regarding the potency and fate of Neuropeptides compared to small-molecule transmitters, which statement is correct?

- A) Neuropeptides are less potent and released in larger quantities
- B) Neuropeptide vesicles are recycled and reused multiple times
- C) Neuropeptides are more potent and their vesicles typically undergo autolysis after release
- D) Neuropeptides are synthesized locally at the axon terminal
- E) Neuropeptides cause rapid, acute responses that last for milliseconds only

The answer is (C)

5. Destruction of dopamine-producing neurons in the nigrostriatal pathway is the primary pathophysiological hallmark of which disorder?

- A) Alzheimer's disease
- B) Depression
- C) Parkinson's disease
- D) ADHD
- E) Psychosis

The answer is (C)

6. A scientist is studying a neurotransmitter secreted by the Raphe nucleus that regulates mood, sleep, and appetite. Low levels of this transmitter are clinically linked to depression. Identify this transmitter:

- A) Norepinephrine
- B) Epinephrine
- C) Serotonin (5-HT)
- D) Oxytocin
- E) Dopamine

The answer is (C)